Primary source: Commure, November 16, 2026, Mountain View
On November 16, 2026, Commure said it acquired Elaborate, which it calls the clinical intelligence platform that cures the inbox. Terms were not disclosed. Elaborate works inside the EHR, on protocols the organization's clinicians control. If you sell coding or denials software against Commure, this deal is not a billing product. It is the after-visit message queue, folded into a platform that already says it codes the claim and handles denials.
Commure says health systems using Elaborate have seen up to 36% less time in the inbox, a 15% reduction in patient message volume, and 97% clinician alignment with automation. Those are company claims. The release does not name the systems.
| Element | What the release says |
|---|---|
| Buyer | Commure, datelined Mountain View, November 16, 2026. The release says tens of millions of appointments a year already run through Commure, at organizations from HCA Healthcare to independent practices. |
| Target | Elaborate. Nicole Bocskocsky is founder and CEO. Available today, on its own or alongside Commure's ambient documentation, coding, and revenue cycle solutions. Forward-deployed engineers tailor the protocols. |
| What Elaborate does | Works inside the EHR. Helps patients understand their care before they write in, routes what arrives to the right person on the care team, and automates clinically informed workflows. Protocols are controlled by each organization's clinicians. |
| What Commure says it already does | Agents handle intake, the phones, the note, coding the claim, and denials, on one data model “from the first patient call to the insurance claim.” Elaborate adds the inbox. |
| Scale, as Commure states it | Live in 500+ healthcare organizations, including two of the largest for-profit hospital systems, with 500,000+ users and 7% of American healthcare appointments. The release names HCA. It does not name the second system. |
| Price | Not disclosed. No revenue, no customer count for Elaborate, and no baseline for the 36%, 15%, or 97%. |
The release states that patient portal messages per patient rose 153% between 2020 and 2025, far outpacing office visits, and that clinicians carry the work into evenings and weekends. It does not cite the study behind the 153%. Treat that figure as Commure's sentence.
“Clinicians spend twice as much time on documentation and billing as they do with patients, and LLMs finally take that work off them,” said Tanay Tandon, co-founder and CEO. “Nicole and the Elaborate team built the agent that clears the inbox. Commure runs tens of millions of appointments a year. Put the two together and these agents can impact tens of thousands of active clinicians on the platform from day one.” The “twice as much time” clause is inside his quote. The release does not attach it to a paper.
“At Elaborate, we've proven that with the right clinical context, safeguards, and institutional preferences, it's possible to automate complex, clinically informed tasks in a way that clinicians overwhelmingly align with,” said Nicole Bocskocsky. “We're excited to bring that impact to clinicians across the country and deliver on our founding mission: curing the inbox.”
This is RevCycleAI's read.
Inbox automation is clinical operations. A message about a normal lab is not a claim, and this release does not say Elaborate posts a charge or works a denial. Commure's reason for owning it is the bundle. The company already tells the market that its agents handle intake, the note, coding, and denials. Adding the inbox means one vendor sits on more of the work between the visit and the bill, including work that never becomes a bill.
That matters if you sell a point coding or denials product into a health system that has already standardized on Commure. It matters less if your buyer never puts the message queue in the revenue-cycle contract. The release says Elaborate can be bought on its own. It does not say whether inbox customers are being moved onto the coding product, and it does not say the 36% inbox cut showed up in collections.
RevCycleAI has covered two earlier Commure facts that should stay separate from this one. The $70 million raise at a $7 billion valuation was a financing, not this acquisition. The Ob Hospitalist Group deployment was a company-reported cut in charge-entry time. This deal runs the other direction: not deeper into the claim, but into the work clinicians do after the patient leaves. The revenue-cycle consequence shows up only if that position keeps coding and denials in the same contract.
Commure bought Elaborate for an undisclosed price. The product is inbox automation inside the EHR, and the 36%, 15%, and 97% figures are the company's claims about unnamed health systems. The RCM fact in the release is the bundle: Commure already says its agents code the claim and handle denials.
Ask whether the inbox agent is in the revenue-cycle contract or beside it. A point vendor that only codes, or only works denials, is now competing with a platform that wants the message queue too. The price was not disclosed. The second for-profit system was not named. No collection result was printed, and none is inferred here.
What was bought, what the company claims, and what still is not a denial rate.
Sources: Commure, “Commure Acquires Elaborate to Cure the Clinician Inbox,” November 16, 2026, Mountain View (page opened). Quotes from Tanay Tandon and Nicole Bocskocsky are verbatim from that release. The 36%, 15%, 97%, 500+ organizations, 500,000+ users, 7% of appointments, HCA reference, and “tens of millions of appointments” are the company's. The 153% message-growth sentence is the release's and is not tied there to a cited study. No price was disclosed, and none is estimated.